 RBC Capital Markets has lowered the price target on Inovio Pharmaceuticals Inc NASDAQ: INO to 4 from 5 with a Sector Perform rating. The analysts updated the model to reflect the evolution of the programs to date and as new leadership gained traction since the CEO change in. 